Dr. Wade Thomas Iams, MD

Dr. Iams practices at Tennessee Oncology in Chattanooga, Tennessee.

Dr. Iams' NPI, 1134485410, was assigned on April 11, 2012. Dr. Iams graduated from University of Michigan Medical School in 2012. Dr. Iams holds Tennessee license 50625.

Dr. Iams' primary practice is Tennessee Oncology, at 605 Glenwood Dr, Chattanooga, TN 37404 in Hamilton County. The practice phone is (615) 329-0570.

Dr. Iams' primary practice is Tennessee Oncology in Chattanooga, Tennessee. Dr. Iams is also affiliated with Ascension Saint Thomas Hospital West. The medical group on file is Tennessee Oncology. Dmand AI also links Dr. Iams to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Iams practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Iams' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Iams is licensed in Tennessee.

CMS data shows 1,031 Medicare services from Dr. Iams across 12 procedure codes in 2024, for 190 Medicare patients. Medicare paid $35,599 for them.

CMS counts 190 Medicare patients who saw Dr. Iams in 2024. The largest group is 65 to 74, with 91 patients. 75% of them have cancer, and 72% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Iams' median patient age at 70, with 57% women.

In 2024, Dr. Iams wrote 1,532 Medicare Part D claims for 142 patients. 75% of them were for generic drugs. CMS names the drug for 1,171 of them, across 40 drugs with 11 or more claims each, at $1,404,473 in total drug cost. In 2023, CMS named 1,599 claims across 57 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Iams for performance year 2024, reported through an alternative payment model (APM). Dr. Iams accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 72 papers to Dr. Iams, published from 2013 to 2025. 2024 was the busiest year, with 11. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Iams has published most often in JTO Clin Res Rep. Dr. Iams' most frequent co-authors are Sally J. York, MD, PhD, David R. Camidge, MD and Christopher Gerald Cann, MD.

Dmand AI links Dr. Iams to 6 clinical trials, 4 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Neoplasm Metastasis, Neoplastic Processes and Carcinoma, Non-Small-Cell Lung. EMD Serono Research & Development Institute, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Iams that name 1 trial.

CMS Open Payments shows 464 general payments to Dr. Iams from 31 drug and device companies from 2019 to 2025. Speaker and faculty fees make up the largest share, 44% of the total. Amgen Inc. paid the most, $168,138. It also lists 4 research payments totaling $111 in 2023, naming 1 clinical trial.

Dr. Iams graduated from University of Michigan Medical School in 2012.